Henry Shelford, CEO and Co-Founder of ADHD UK, was quoted in the article and provided background information.
According to NHS data, nearly 278,000 patients in England were prescribed central nervous system stimulants and other medications for attention deficit hyperactivity disorder (ADHD) in the past year, marking an 18% increase from the previous year. This rise is attributed to heightened awareness and more frequent diagnoses, particularly among adults and women. Experts suggest that the growing recognition of ADHD’s impact on adults, along with increased media coverage and public discourse, has contributed to more individuals seeking assessments and treatment. However, this surge has also led to concerns about overdiagnosis and the potential for medication shortages, prompting calls for a balanced approach to diagnosis and treatment.
You can read the full article here: https://www.theguardian.com/society/article/2024/jul/26/record-numbers-in-england-taking-adhd-medication-nhs-data-shows
